FDA Grants Priority Review for New Leukemia Option

The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug ’s developer. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uOgWS5
via IFTTT